Edition:
United States

Trillium Therapeutics Inc (TRIL.OQ)

TRIL.OQ on NASDAQ Stock Exchange Capital Market

6.75USD
22 Feb 2018
Change (% chg)

-- (--)
Prev Close
$6.75
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
27,422
52-wk High
$13.30
52-wk Low
$4.10

Chart for

About

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is... (more)

Overall

Beta: 2.08
Market Cap(Mil.): $114.38
Shares Outstanding(Mil.): 13.15
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 189.80 16.52
EPS (TTM): -- -- --
ROI: -- -0.65 36.19
ROE: -- -3.21 17.38

BRIEF-Trillium Therapeutics Inc Files For Mixed Shelf Of Upto $150 Mln

* TRILLIUM THERAPEUTICS INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING Source text : http://bit.ly/2jZxGi0 Further company coverage:

Dec 15 2017

BRIEF-Matrix Capital Management Co Reports A 16.5 Pct Passive Stake In Trillium Therapeutics

* MATRIX CAPITAL MANAGEMENT COMPANY LP REPORTS A 16.5 PCT PASSIVE STAKE IN TRILLIUM THERAPEUTICS INC AS OF NOV 30 - SEC FILING Source text: (http://bit.ly/2yOHuTW) Further company coverage:

Dec 08 2017

BRIEF-Trillium announces private placement to fund development of cancer drugs

* Trillium Therapeutics - ‍entered into subscription agreements for sale of 1.95 million shares & 400,000 Series II non-voting convertible first preferred shares​

Nov 15 2017

BRIEF-Trillium Therapeutics reports Q3 results

* Trillium Therapeutics reports third quarter 2017 financial and operating results

Nov 10 2017

Earnings vs. Estimates